PLUS1
38.38
-0.63 (-1.61%)
-0.63 (-1.61%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| FibroGen Inc | FGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.63 | -1.61% | 38.38 | 17:17:36 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 38.38 | 37.54 | 38.85 | 38.54 | 39.01 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 38.38 | 44.80 | 6.42 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,574 | 611,164 | $ 38.31 | $ 23,411,996 | 675,881 | 22.65 - 53.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:59:15 | 1 | $ 38.38 | USD |
FibroGen Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.47B | 90.36M | 78.92M | $ 256.58M | $ - | -0.96 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
FibroGen News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/29/2020 | 07:00 | GlobeNewswire Inc. | FibroGen to Report Third Quarter 2020 Financial Results |
| 10/22/2020 | 10:08 | GlobeNewswire Inc. | FibroGen Presents Late-Breaker Abstract Results on.. |
| 10/14/2020 | 07:00 | GlobeNewswire Inc. | FibroGen to Present New Efficacy and Safety Analyses from.. |
| 10/02/2020 | 07:00 | PR Newswire (US) | New Ventures Funds Rebrands as Scientia Ventures |
| 9/18/2020 | 17:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/17/2020 | 18:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/10/2020 | 19:36 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FGEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 45.93 | 46.36 | 37.50 | 40.09 | 808,643 | -7.55 | -16.44% |
| 1 Month | 40.46 | 49.70 | 37.50 | 43.64 | 637,681 | -2.08 | -5.14% |
| 3 Months | 44.00 | 53.97 | 37.50 | 43.27 | 724,004 | -5.62 | -12.77% |
| 6 Months | 38.89 | 53.97 | 32.12 | 40.90 | 698,831 | -0.51 | -1.31% |
| 1 Year | 39.28 | 53.97 | 22.65 | 39.92 | 719,623 | -0.90 | -2.29% |
| 3 Years | 55.65 | 68.55 | 22.65 | 45.16 | 624,678 | -17.27 | -31.03% |
| 5 Years | 23.64 | 68.55 | 14.38 | 39.62 | 570,424 | 14.74 | 62.35% |
FibroGen Description
| FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. |
